

1.6.5.1.1	Angiostatin	23
1.6.5.1.2	Endostatin	23
1.6.5.2	Drugs that block endothelial cell proliferation	24
1.6.5.3	VEGF Inhibitors	25
1.6.6	Thalidomide	26
1.6.7	Lenalidomide	27
1.6.8	Linomide	28
1.6.9	Veliparib, ABT-888	29
1.6.10	Bevacizumab (Avastin)	30
1.7	Aim of investigation	31
	<b>Chapter two</b>	33
2	Materials and methods	34
2.1	Chemicals	34
2.2	Instrumentation	34
2.3	Methods and Experimental molecular docking	34
2.4	Synthesis of 2-methyl-1-(prop-2-yn-1-yl)-2,3-dihydro-1H-indole (AZ-1)	37
2.5	Synthesis of: 2-methyl-1-[4-(amino-1-yl)but-2-yn-1-yl]-2,3-dihydro-1H-indole AZ2-AZ7	39
2.5.1	Preparation of 1-[4-(2,6-dimethylpiperidin-1-yl)but-2-yn-1-yl]-2-methyl-2,3-dihydro-1H-indole (AZ-2)	42
2.5.2	Preparation of 2-methyl-1-[4-(4-methylpiperazin-1-yl)but-2-yn-1-yl]-2,3-dihydro-1H-indole (AZ-3)	43
2.5.3	Preparation of 2-methyl-1-[4-(2-methylpiperidin-1-yl)but-2-yn-1-yl]-2,3-dihydro-1H-indole (AZ-4)	44
2.5.4	Preparation of 2-methyl-1-[4-(piperidin-1-yl)but-2-yn-1-yl]-2,3-dihydro-1H-indole (AZ-5)	45
2.5.5	Preparation of 2-methyl-1-[4-(pyrrolidin-1-yl)but-2-yn-1-yl]-2,3-dihydro-1H-indole (AZ-6)	46
2.5.6	Preparation of 1-[4-(azepan-1-yl)but-2-yn-1-yl]-2-methyl-2,3-dihydro-1H-indole (AZ-7)	47